DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Analysts

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $12.3333.

Several research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, October 8th. TD Cowen started coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on shares of DiaMedica Therapeutics in a research report on Friday, November 14th. They set an “overweight” rating for the company. Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th.

DiaMedica Therapeutics Stock Down 0.2%

Shares of DiaMedica Therapeutics stock opened at $8.14 on Tuesday. The stock’s 50-day simple moving average is $7.96 and its 200-day simple moving average is $6.53. DiaMedica Therapeutics has a 52 week low of $3.19 and a 52 week high of $10.42. The company has a market capitalization of $423.93 million, a price-to-earnings ratio of -11.46 and a beta of 1.15.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, equities analysts expect that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

Insider Activity at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg purchased 73,099 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was bought at an average cost of $8.57 per share, with a total value of $626,458.43. Following the completion of the purchase, the insider owned 8,825,742 shares in the company, valued at approximately $75,636,608.94. This represents a 0.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders bought 1,061,277 shares of company stock valued at $7,632,627 in the last quarter. 7.30% of the stock is currently owned by insiders.

Institutional Trading of DiaMedica Therapeutics

Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada boosted its position in shares of DiaMedica Therapeutics by 46,879.1% during the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after acquiring an additional 154,701 shares during the last quarter. Goldman Sachs Group Inc. increased its position in DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock worth $462,000 after purchasing an additional 52,854 shares during the last quarter. Jane Street Group LLC raised its stake in DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after purchasing an additional 58,457 shares in the last quarter. Perigon Wealth Management LLC bought a new position in DiaMedica Therapeutics during the second quarter valued at $207,000. Finally, World Investment Advisors grew its stake in shares of DiaMedica Therapeutics by 24.7% in the 2nd quarter. World Investment Advisors now owns 31,975 shares of the company’s stock worth $125,000 after buying an additional 6,325 shares in the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.